FDA authorizes Pfizer-BioNTech COVID-19 vaccine for adolescents

By The Science Advisory Board staff writers

May 11, 2021 -- The U.S. Food and Drug Administration (FDA) expanded the emergency use authorization (EUA) for the Pfizer-BioNTech COVID-19 vaccine to include adolescents ages 12 to 15 years.

The EUA was originally issued on December 11, 2020, for administration in individuals 16 years of age and older. The FDA determined that the vaccine met the statutory criteria to amend the EUA, and that the known and potential benefits in individuals 12 years of age and older outweigh the known and potential risks.

The agency evaluated the safety of the vaccine in a population of 2,260 participants ages 12 to 15 years old that are enrolled in an ongoing randomized, placebo-controlled clinical trial in the U.S. Of these, 1,131 participants received the vaccine and 1,129 received a saline placebo. According to the sponsor, more than half of the participants were followed for safety for at least two months following the second dose.

The effectiveness of the vaccine was evaluated by comparing the immune response to the vaccine in 190 participants, 12 to 15 years of age, to the immune response of 170 participants, 16 to 25 years of age. The agency found that the response in younger adolescents was at least as good in the older group. Moreover, the vaccine was 100% effective in preventing COVID-19.

Pfizer, BioNTech initiate rolling submission of BLA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday that they have started a biologics license application (BLA) with the U.S. Food and Drug Administration for approval...
Pfizer, BioNTech submit expanded CMA to EMA for COVID-19 vaccine
Pfizer and BioNTech announced on Friday they have submitted a variation to the conditional marketing authorization (CMA) for use of their COVID-19 vaccine...
Pfizer, BioNTech confirm high efficacy of COVID-19 vaccine up to 6 months
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine is 91.3% effective against the virus six days through up to six months after the second dose, according to...
Pfizer-BioNTech's COVID-19 vaccine shows 100% effectiveness in adolescents
Pfizer-BioNTech's BNT162b2 COVID-19 vaccine demonstrated 100% efficacy and robust antibody responses in people between the ages of 12 and 15, according...

Copyright © 2021 scienceboard.net


Conferences
CPhI North America
August 10-12
Philadelphia, Pennsylvania United States
Bioprocessing Summit
August 16-19
Boston, Massachusetts United States
6th Annual CAR-TCR Summit
August 30 - September 2
Online
European Congress of Immunology (ECI) 2021
September 1-4
Belgrade Serbia
Medical Affairs Strategic Summit (MASS)
September 13-15
New Brunswick, New Jersey United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter